Article

Alterations in bone turnover in HIV-positive patients.

Infectious Disease Unit, University of Granada Hospital, School of Medicine, University of Granada, Spain.
Infection (Impact Factor: 2.86). 21(4):220-2.
Source: PubMed

ABSTRACT Changes in mineral metabolism have recently been described in AIDS patients. To determine whether such changes affect bone turnover and bone mass, we studied 16 HIV-seropositive patients, classified according to Centers for Disease Control criteria, and 27 healthy controls. Biochemical markers of bone turnover and bone mineral density were analyzed. Serum concentrations of osteocalcin were abnormally low (0.5 +/- 1.3 ng/ml) in HIV-seropositive patients, in comparison with the control group (2.98 +/- 1.6 ng/ml) (p < 0.05). Urinary calcium/creatinine ratio was also decreased in HIV-positive patients (0.10 +/- 0.09 vs 0.14 +/- 0.09) (p < 0.05). In addition, bone mass was slightly lower in HIV-seropositive patients, although the difference was not statistically significant. The pathogenic mechanism of these alterations and their clinical relevance still remain unclear, and several factors may be implicated.

0 Bookmarks
 · 
49 Views
  • Medicina Clínica 01/2002; 119(3):103–108. · 1.25 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Life expectancy and quality of life among human immunodeficiency virus (HIV-1)-infected patients has dramatically improved with the advent of highly active antiretroviral therapy (HAART). However, with the transformation of HIV infection into a chronic disease, a series of long-term consequences, including osteoporosis, has emerged.Bone mass is lower in patients with HIV-1 infection than in healthy individuals and the prevalence of osteopenia and osteoporosis is higher. The incidence and prevalence of fragility fractures does not appear to be on the increase; however, as the HIV-infected population ages, an increase in fragility fractures can be expected. The causes that favor the occurrence of bone-related disorders are multiple and are related to HIV infection and its treatment.
    Seminarios de la Fundación Española de Reumatología 09/2007; 8(3):154–164.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Concern has been raised that HIV infection, its treatment, or both adversely affect skeletal health. Cross-sectional studies show that bone mineral density (BMD) is 3-5% lower in patients infected with HIV than in uninfected controls, but patients with HIV infection are, on average, 5 kg lighter than uninfected people. After this weight difference is accounted for, BMD differences are smaller and not clinically relevant. Longitudinal studies show short-term BMD loss of 2-4% over 1-2 years when antiretroviral therapy is started, followed by longer periods of BMD increase or stability. Losses are greatest with treatment regimens that contain tenofovir. Patients infected with HIV have slightly higher fracture rates than controls, but the increased risk of fracture is substantially attenuated by adjustment for traditional risk factors for fracture. These reassuring findings suggest that management of skeletal health in HIV should follow guidelines for the general population. In general, effective antiretroviral treatment and avoidance of undernutrition are the two most important factors for maintenance of skeletal health in patients infected with HIV.
    The lancet. Diabetes & endocrinology. 02/2014;

José Hernández-Quero